Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Kala Pharmaceuticals Inc

Healthcare US KALA

2.06USD
-0.17(7.62%)

Last update at 2026-06-05T20:00:00Z

Day Range

2.032.30
LowHigh

52 Week Range

5.1018.20
LowHigh

Fundamentals

  • Previous Close 2.23
  • Market Cap18.36M
  • Volume124096
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-40.56800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 1.33M
  • Diluted EPS TTM-14.56

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -44.82200M -142.60500M -104.32700M -94.34700M -66.73800M
Minority interest - - - - -
Net income -0.22300M -152.29600M -112.00400M -101.98400M -66.73800M
Selling general administrative 65.03M 105.06M 81.07M 65.02M 35.43M
Selling and marketing expenses - - - - -
Gross profit 1.33M 7.14M 3.19M 4.07M 0.00000M
Reconciled depreciation 0.54M 0.97M 0.91M 0.84M 0.95M
Ebit -81.35600M -109.43300M -96.23100M -88.22400M -63.98900M
Ebitda -81.61800M -107.04300M -95.73800M -85.86700M -63.03400M
Depreciation and amortization -0.26200M 2.39M 0.49M 2.36M 0.95M
Non operating income net other - - - - -
Operating income -81.35600M -109.43300M -96.23100M -88.22400M -64.72100M
Other operating expenses 85.25M 120.67M 102.59M 94.30M 64.72M
Interest expense 7.27M 8.38M 8.59M 8.48M 3.31M
Tax provision - - - - -
Interest income 0.66M 0.10M 0.49M 2.36M 1.69M
Net interest income -6.60200M -8.27600M -8.09600M -6.12300M -1.62700M
Extraordinary items - - - - -
Non recurring - - 8.59M 8.48M 3.31M
Other items - - - - -
Income tax expense -44.59900M 9.69M 7.68M 7.64M 1.30M
Total revenue 3.89M 11.24M 6.36M 6.07M 0.00000M
Total operating expenses 82.69M 116.58M 99.42M 92.29M 64.72M
Cost of revenue 2.56M 4.10M 3.17M 2.01M 0.00000M
Total other income expense net 36.53M -33.17200M -8.09600M -6.12300M -0.39000M
Discontinued operations - - - - -
Net income from continuing ops -44.82200M -142.60500M -96.23100M -94.34700M -66.73800M
Net income applicable to common shares -44.82200M -142.60500M -104.32700M -94.34700M -66.73800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 55.95M 86.82M 139.43M 221.61M 154.32M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.74M 1.28M 3.18M 2.15M 1.59M
Total liab 48.45M 67.85M 122.62M 121.61M 124.63M
Total stockholder equity 7.50M 18.97M 16.80M 100.00M 29.69M
Deferred long term liab - - - - -
Other current liab 6.02M 13.65M 3.82M 18.97M 20.93M
Common stock 0.00300M 0.00200M 0.07M 0.06M 0.04M
Capital stock 0.00300M 0.00200M 0.07M 0.06M 0.04M
Retained earnings -629.40900M -587.21000M -542.38800M -399.78300M -295.45600M
Other liab - 4.22M 5.72M - -
Good will - - - - -
Other assets - 0.46M 11.04M 47.06M 16.36M
Cash 50.90M 70.50M 92.14M 77.26M 85.45M
Cash and equivalents - - - - -
Total current liabilities 8.35M 25.68M 37.42M 22.23M 24.77M
Current deferred revenue 1.07M 4.19M 28.00M - -
Net debt -14.57200M -27.54500M -11.94800M 23.65M 15.73M
Short term debt 0.33M 5.01M 0.71M 1.53M 1.33M
Short long term debt - 5.00M - - -
Short long term debt total 36.32M 42.95M 80.19M 100.92M 101.18M
Other stockholder equity 636.91M 606.18M 559.13M 499.71M 325.11M
Property plant equipment - 0.42M 4.02M 9.38M 32.48M
Total current assets 52.87M 85.94M 124.37M 171.38M 105.48M
Long term investments - - - - -
Net tangible assets - 18.97M 16.80M 100.00M 29.69M
Short term investments - - 0.00000M 76.28M 0.70M
Net receivables 0.24M 6.50M 17.45M 9.85M 13.10M
Long term debt 34.19M 37.94M 78.93M 72.24M 71.18M
Inventory - 7.67M 8.64M 5.23M 4.65M
Accounts payable 0.92M 2.83M 4.90M 1.72M 2.52M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - 0.00400M -2.51600M
Additional paid in capital - - - - -
Common stock total equity - - - 0.06M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -399.78300M -295.45600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.30M 0.46M 11.04M 19.21M 16.36M
Deferred long term asset charges - - - - -
Non current assets total 3.08M 0.88M 15.06M 50.23M 48.84M
Capital lease obligations 2.13M 0.01M 1.26M 28.67M 30.00M
Long term debt total - - - 72.24M 71.18M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 62.72M 70.80M -76.26700M -1.33500M -1.57800M
Change to liabilities -2.07600M 3.23M -2.68700M 6.86M 8.06M
Total cashflows from investing activities 62.72M 70.80M -78.20900M -1.33500M -1.57800M
Net borrowings -40.03900M 1.96M -0.03200M -0.03000M 74.66M
Total cash from financing activities -7.94200M 42.55M 160.63M 8.98M 124.10M
Change to operating activities -14.27900M -1.83400M -2.24000M 6.67M 2.16M
Net income -44.82200M -142.60500M -104.32700M -94.34700M -66.73800M
Change in cash -24.13300M 5.12M -8.27500M -85.07300M 68.41M
Begin period cash flow 94.88M 89.76M 98.03M 183.10M 114.70M
End period cash flow 70.75M 94.88M 89.76M 98.03M 183.10M
Total cash from operating activities -78.90800M -108.23500M -90.69400M -92.72000M -54.12100M
Issuance of capital stock 31.80M 41.23M 158.56M 8.43M 70.77M
Depreciation 0.54M 0.97M 0.91M 0.84M 0.95M
Other cashflows from investing activities - - -1.94200M - 12.21M
Dividends paid - - - - -
Change to inventory 1.71M -6.25700M -2.36800M -4.27100M -3.86800M
Change to account receivables 15.14M -5.75600M 1.96M -11.56300M -157.85500M
Sale purchase of stock - 1.58M 160.66M 9.01M 71.30M
Other cashflows from financing activities 0.30M 79.37M 2.10M 0.59M 75.19M
Change to netincome -36.53900M 42.49M 13.31M 9.99M 9.01M
Capital expenditures 0.31M 0.89M 1.94M 1.33M 1.58M
Change receivables - - 1.96M -11.56300M -
Cash flows other operating - - 1.45M -0.23300M -0.92800M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -8.27500M -85.07300M 68.41M
Change in working capital 0.49M -10.61600M -3.57300M -11.93800M 2.38M
Stock based compensation 7.01M 16.09M 13.31M 9.99M 8.62M
Other non cash items -42.12200M 22.51M 2.99M 2.73M 0.27M
Free cash flow -79.22100M -109.12100M -92.63600M -94.05500M -55.69900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
KALA
Kala Pharmaceuticals Inc		 -0.17 7.62% 2.06 - - 1.16 2.70 0.04 -0.1582
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Kala Pharmaceuticals Inc

1167 Massachusetts Avenue, Arlington, MA, United States, 02476

Key Executives

Name Title Year Born
Mr. Mark T. Iwicki Chairman & CEO 1966
Mr. Todd Bazemore Pres & COO 1970
Dr. Kim Brazzell Ph.D. Head of R&D and Chief Medical Officer 1953
Dr. Justin Hanes Ph.D. Founder & Chair of the Scientific Advisory Board NA
Ms. Mary Reumuth CPA, CPA CFO & Treasurer 1975
Ms. Jill S. Steier Exec. Director of Investor Relations & Corp. Communications NA
Mr. Eric L. Trachtenberg Gen. Counsel, Chief Compliance Officer & Corp. Sec. 1973
Ms. Michele LaRussa Sr. VP of Regulatory Affairs & Quality Assurance 1970
Mr. Vincent Kosewski Sr. VP of Manufacturing & Supply Chain Management 1963
Mr. James Patnoe Sr. VP of Market Access, Commercial Operations & Pricing NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.